Objective: This study aimed to compare the efficacy and safety of quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis in a randomized, open-label, blinded-rater, parallel group trial.
D
rug-induced psychosis is a common complication in patients with Parkinson disease (PD) and is the major factor leading to their placement in nursing homes. 1 Psychotic symptoms including hallucinations, delusions, confusion, and disorientation have been reported to occur in about 16-40% of parkinsonian patients chronically treated with dopaminergic drugs. 2, 3 They are more frequent in patients with cognitive impairment, 4 depression, 2 a longer disease duration, 5 higher age at onset, 4 sleep disorder, 6 akinetic form of PD, 7 dose and duration of treatment with L-dopa 2,4,5 and dopamine agonists, 4, 8 and the apolipoprotein E4 allele. 9 Traditional treatment options included either reducing the dosage of antiparkinsonian medication or using typical antipsychotics. Both strategies were unsatisfactory and could lead to worsening of motor disability.
The introduction of atypical antipsychotics with low potential of causing extrapyramidal adverse effects has represented a promising option for treating psychosis in PD. 10 Currently, clozapine is considered the drug of choice in this condition. In this respect, double-blind studies have indicated that clozapine may improve psychosis without causing a significant exacerbation of parkinsonism. 11, 12 However, its use is limited by the potential risk of developing agranulocytosis, which is estimated between 0.4-2%, 13 requiring weekly leukocyte monitoring. While other newer antipsychotics, such as risperidone and olanzapine, have been reported to worsen parkinsonian motor function, 14, 15 a number of uncontrolled studies have documented that quetiapine may improve psychotic symptoms in patients with PD, without compromising motor function. [16] [17] [18] [19] [20] Quetiapine is a dibenzothiazepine agent, structurally similar to clozapine, 21 with moderate affinity for the D2 and 5HT2 receptors with a higher 5HT2A relative to D2 receptors. 22 While no randomized controlled studies have evaluated the efficacy of quetiapine in PD psychosis, open trials have indicated that this agent, in variable dosage, is effective and well tolerated in treating PD dopaminergic psychosis. [16] [17] [18] [19] [20] The aim of the present study was to investigate the efficacy and safety of quetiapine vs. clozapine in parkinsonian patients with dopaminergic psychosis.
MATERIALS AND METHODS
Patients consecutively attending the Parkinson Unit at Institute of Neurology, University of Messina, were eligible for the study if they had idiopathic PD defined by the criteria of Gelb et al. 23 and psychosis induced by antiparkinsonian drugs. To be included in the study, each patient had to have a documented history of L-dopa or L-dopa plus dopamine agonist drug-induced psychosis of at least 4 weeks before study entry and required a baseline score of Ն3 on the items hallucinations or unusual thought content (or delusions) of the Brief Psychiatric Rating Scale (BPRS). 24 There was no history of psychotic symptoms before the patients received the diagnosis of PD or treatment with dopaminergic drugs. Exclusion criteria were a history of leukopenia, dementia (Mini Mental State Examination score <24) or any primary psychiatric illness including schizophrenia, psychotic depression, or bipolar disorder; history of epilepsy; presence of any underlying intermittent diseases causing psychosis; presence of cardiovascular diseases or symptomatic orthostatic hypotension; or use of antipsychotic agents in the past 6 months. All patients fulfilling the inclusion criteria signed informed consent. A local ethics committee approved the protocol, patient information, and consent. The study was a randomized, open-label, blinded-rater, parallel group trial. Each patient was assigned to receive either quetiapine or clozapine on the basis of a predetermined list of randomization. Both drugs were given at a low initial dose (6.25 mg/d for clozapine and 25 mg/d for quetiapine), administered orally, once or twice daily. The antipsychotic dose was then titrated by an unblinded neurologist up to a maximum of 50 mg/d for clozapine and 200 mg/d for quetiapine, according to the individual clinical response and tolerability. The duration of the trial was 12 weeks. During the study, the dosage of antiparkinsonian drugs was kept constant. All patients were assessed at baseline and after 2, 4, 8, and 12 weeks by the same blinded investigators, a neurologist and a psychiatrist. Patients were instructed not to reveal the treatment allocation to the raters. Moreover, patients under treatment did not present peculiar clinical findings that could unmask their status to the raters. The severity of psychosis was assessed by a blinded psychiatrist using the BPRS and the Clinical Global Impression Scale-Severity Subscale (CGI-S). 25 Five items from the BPRS (hallucinations, suspiciousness, unusual thought content, hostility, and conceptual disorganization) were evaluated to further examine specific symptoms. A scripted interview was performed to complete rating scales. A blinded neurologist assessed the progression of PD during the study period using the Unified Parkinson's Disease Rating Scale (UPDRS III) and dyskinesias by using the Abnormal Involuntary Movement Scale (AIMS). Tolerability was assessed by interview and a medical examination at each study visit. An electrocardiogram and laboratory tests, including hematology, clinical chemistry, and urine analysis, were performed on admission and at the end of treatment. Blood pressure and pulse rate were measured at each study visit. In the clozapine group, a complete blood count was performed weekly.
Sample size calculations were based on previous experiences comparing clozapine to other atypical antipsychotics for treatment of psychosis in PD; 14, 15 with 40 subjects, 20 for each treatment group, there was a 92% power to detect a 6-point difference (SD, 5 points) in the BPRS score between the groups at a significance ␣ level of 0.05. Analysis of covariance with repeated measures (group × time), with the baseline values as covariates, was used to detect between-and withingroup differences in efficacy and safety variables. Statistical significance was defined as P < 0.05. 
RESULTS
Forty-five patients fulfilled the inclusion criteria and participated in the study: 23 received clozapine and 22 quetiapine. Three patients in the clozapine group did not complete the trial: one dropped out for dizziness in week 1, one for severe hypotension at week 2, and one for oversedation at week 3. In the quetiapine group, one patient withdrew for oversedation at week 1, and one for confusional state at week 2. Forty patients, 20 (10 men and 10 women) on clozapine and 20 (10 men and 10 women) on quetiapine, completed the study and were included in the clinical analysis. The demographic and clinical characteristics of both treatment groups are reported in Table 1 . In the clozapine group, the final dose of clozapine ranged from 12.5-50 mg/d (mean dose 26 ± 12 mg/d), while in the quetiapine group, final dose ranged from 25-200 mg/d (mean dose 91 ± 47 mg/d). L-dopa dosage ranges were 710 ± 165 mg in the clozapine group and 687 ± 163 mg in the quetiapine group. Five patients in the clozapine group were also receiving dopamine agonists (3 with pergolide, at daily dose of 1.5-4.5 mg, and 2 with ropinirole at daily doses of 9 mg and 15 mg). In the quetiapine group 4 patients were also treated with dopamine agonists (2 with pergolide, at daily dose of 3 mg, and 2 with ropinirole at daily dose of 12 mg).
The results of the study are summarized in the Table 1 . There were no significant differences in any of the behavioral and motor function parameters between the clozapine and quetiapine groups at baseline. The psychopathologic state, as assessed by the BPRS, total and items hallucinations, suspiciousness, unusual thought content, hostility, and conceptual disorganization, and by the CGI-S, improved significantly (P < 0.001) from baseline to week 12 in both treatment groups. As shown in Figure 1 , no differences in the mean BPRS total scores were found between clozapine and quetiapine groups at each assessment time. The UPDRS III score was almost unchanged in both treatment groups. However, in the 3 patients receiving a quetiapine dose higher than 100 mg/d, a slight worsening of parkinsonism was observed. The AIMS score also decreased significantly (P < 0.05) in both treatment groups during the study period. Side effects were mild in both groups. In particular, subjective adverse side effects included worsening movement (n = 3), sedation (n = 1), and dizziness (n = 1) in the quetiapine group; and drooling (n = 1), weight gain (n = 1), and sedation (n = 1) in the clozapine group.
DISCUSSION
The present investigation has several shortcomings including the small sample size and the unblinded nature of the patients. In addition, the raters, although blinded, may have been biased toward a possibly equal effect in both groups, as they were aware of the study design. Despite these limitations, to our knowledge this is the first single-blind head-to-head evaluation of quetiapine vs. clozapine in the treatment of dopaminergic psychosis in PD patients. The results of this study indicate that quetiapine may be an effective and well-tolerated agent in this condition, thus confirming earlier observations from clinical open trials. [16] [17] [18] [19] [20] In fact, quetiapine, at a mean dose of 91 ± 47 mg/d, was as effective as clozapine, at a dose of 26 ± 12 mg/d, in reducing dopaminergic psychosis in PD pa- 11 Neither treatment provoked worsening of parkinsonism, as indicated by the absence of significant changes in the UPDRS III total and single item scores, such as gait, posture, rapid alternating movements of the hands, and rigidity, during the study period. However, the 3 patients in the quetiapine group receiving the higher dose showed a mild exacerbation of parkinsonism. Conversely, in the clozapine group, the UPDRS III total score decreased slightly but not significantly, due to a not significant reduction of the score in the tremor item. Furthermore, AIMS score improved significantly in both groups. Adverse effects were mild, generally transient, and well tolerated.
The results of previous studies on the use of quetiapine in dopaminergic PD psychosis are somewhat contradictory with regard to the optimal antipsychotic dose. 17, 26, 27 Our findings suggest the use of a quetiapine dose around 100 mg/d. As a higher dose may be associated with a mild reduction in motor function, more caution is needed when going above 100 mg/d.
During the advanced phase of PD, dopaminergic psychosis is often associated with the occurrence of dyskinesias that further compromise the quality of life of affected subjects. In our patients, during quetiapine and clozapine treatment, dyskinesias, assessed by AIMS, improved significantly (P < 0.05). These results are consistent with those of earlier investigations showing the efficacy of clozapine in the treatment of involuntary movements in patients with Huntington chorea, 28 tardive dyskinesia, 29 and levodopa-induced dyskinesias. 30 To our knowledge, so far no studies have documented the benefit of quetiapine on levodopa-induced dyskinesias in patients with PD.
In conclusion, we believe that clozapine or quetiapine, at low doses, may represent the first approach to the treatment of dopaminergic psychosis. Double-blind, randomized controlled studies are needed to verify which of these agents should be considered as the first-line option in the treatment of drug-induced psychosis in PD patients.
